Human parathyroid glands from a patient with chronic renal failure were used to study in vitro biosynthesis of immunoreactive parathyroid hormone. Parathyroid glands were incubated in the presence of [3Hlleu-cine, and classical subcellular fractions were prepared. Peptides from acetic acid extractions of the fractions were separated on Sephadex G-75 Superfine. Eluates were assayed for immunoreactive parathyroid hormone by a double-antibody technique. Leucine was incorporated into several large immunoreactive peptides of parathyroid hormone having estimated molecular weights of >25,000, 18,000, and 13,000. The large forms of immunoreactive parathyroid hormone were prominant in the microsomes. The secretion granule fraction, as well as the patient's serum, contained principally immunoreactive parathyroid hormone with an apparent molecular weight of 10,000.
We have previously demonstrated the existence of immunoreactive peptides of human parathyroid hormone (PTH) that have apparent molecular weights larger than that of highly purified bovine PTH, which has a molecular weight of 9500 (1) . Furthermore, we have found in studying the subcellular fractions of human parathyroid tissue that the immunoreactive peptides larger than purified bovine PTH can be localized to the microsome fraction of the gland, which contains protein synthetic components of the cell. From this information we have postulated that human PTH is synthesized by way of a large precursor molecule that is subsequently cleaved to a peptide with molecular weight of about 10,000 and which may be the principal form of PTH stored in the parathyroid's secretory granules. To test this hypothesis, we have incubated human parathyroid tissue with [8H]-leucine to study the in vitro synthesis of this possible precursor to human PTH.
METHODS
In Vitro Incorporation of [8HjLeucine. Human parathyroid tissue was obtained fresh at the time of subtotal parathyroidectomy on a patient with chronic renal failure. The tissue was kept briefly on ice until dissected free of connective tissue and minced into pieces of about 1 mm. The tissue was incubated in 5 ml of incubation medium which was Kreb's bicarbonate buffer ( F III (microsome fraction) Pellet from 100,000 X g for 60 min F IV Residual soluble fraction incubated for an additional 30 min. After 60 min of incubation, the incubation medium was removed and the tissue was washed twice briefly with ice-cold 0.25 M sucrose. The tissue was homogenized in 5 ml of ice-cold 0.25 M sucrose. A 1-ml aliquot of the homogenate was removed; the remaining suspension was carried through differential centrifugation to obtain subcellular fractions. The speeds and times for centrifugation were identical to those we have used with islet tissue to obtain a secretion granule fraction (2) . The conditions are shown in Table 1 .
To to bovine PTH, designated C-12, was obtained from Dr. Claude Arnaud of the Mayo Clinic, Rochester, Minn. Another chicken antibody to bovine PTH, designated C-6, was prepared in our laboratory and used for all other determinations of immunoreactive PTH. A highly purified bovine PTH (Wilson Laboratories, Chicago, Ill.) was used for standards and for preparation of iodinated bovine PTH by the Hunter and Greenwood method (4). All solutions contained 0.2% human-serum albumin, or 1% bovine-serum albumin and 0.13 M borate buffer (pH 8.4). Incubations were done at 4°.
RESULTS
The results of gel filtration of the homogenate are shown in Fig. 1 Kav 0.52 (estimated molecular weight 10,000) had the lowest apparent specific activity.
In the secretory granule fraction (F II), the immunore- Superfine, and immunoreactive PTH was assayed in each fraction of eluate by antibody C-6 (Fig. 5) . The principal form of immunoreactive PTH in this serum eluted at Kav 0.52, with only small amounts of peptides either earlier or later. For comparison, the elution pattern of highly purified bovine PTH (Wilson Laboratories) is shown in Fig. 6 . The immunoreactive PTH found in this patient's serum eluted at a position only slightly ahead of that found for bovine PTH (K., 0.54) and, therefore, had a molecular weight of about 10,000.
Proteins of known molecular weight were used to calibrate our columns of Sephadex G-75 Superfine (Fig. 7) . Highly purified bovine PTH from Wilson Laboratories was used as one of this series of proteins, and its elution position has been repeatedly determined by the radioimmunoassay with antibody C-6 for detection; it has been consistently found to elute at Ka. 0.53-0.55. Therefore, immunoreactive PTH found at Kay 0.52 not only in homogenates but also in secretion granules from human parathyroid tissue and in uremic serum (Figs. 1, 4 , and 5) has an estimated molecular weight nearly that of bovine PTH, or about 10,000. Immunore- (6) . They allude to the possibility of an even larger polypeptide being the direct product synthesized by the messenger RNA for PTH, a possibility we had suggested (1) . Recently, Habener et al. reported a possible precursor to human PTH found in parathyroid adenomas that has a molecular weight of 11,500 (7) . In none of these reports was there a description of the subcellular distribution of their precursor to PTH.
Our data indicate the existence of a large immunoreactive peptide that has not been previously described. We have shown that our large precursor is seen by two different antibodies to bovine PTH. This large immunoreactive PTH in human parathyroid may be converted to two intermediates, the smaller of which may be the human analog of the pro. PTH in bovine parathyroid as described by Cohn et synthesis of precursors in pathological tissue, the conversion process cannot keep pace with the rate of precursor synthesis. Habener et al., dealing with abnormal human tissue as we have, did not find any form of PTH larger than 11,500 molecular weight. However, there are substantial differences between the approach used by these two laboratories and our approach. We have studied tissue subcellular fractions and the others have not. Whereas we have used relatively mild conditions to prepare the samples for analysis (extraction in 0.2 M acetic acid for 1 hr in the cold), they used the classical urea-HCl extraction procedure and prepared a trichloroacetic acid powder.
All of our data thus far, either from the studies of subcellular distribution of immunoreactive PTH or from the study of the in vitro biosynthesis of PTH, are consistent with the hypothesis that human PTH is synthesized by way of a large precursor molecule (estimated molecular weight in excess of 25,000) and that this precursor is subsequently cleaved to PTH, perhaps by way of two intermediate peptides of 18,000 and 13,000. Human PTH is stored and secreted in a form with a molecular weight of 10,000. These estimates of molecular weight are not considered definitive, since conditions necessary for accurate determination of molecular weight by gel-filtration column chromatography were not met by the methods we used; they are given only as preliminary estimates.
Additional supporting evidence for our hypothesis that might come from assays of the biological activity of these three possible precursors to human PTH, or from enzymatic conversion of them to PTH, cannot be done until sufficient quantities of these materials can be isolated to permit such testing. Definitive testing of any hypothesis regarding a precursor to product relationship requires the determination of the primary structure of the peptides in question, as has been done for insulin and proinsulin.
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